Purpose: To perform a quantitative study of the vascular microstructure in actively treated choroidal neovascularization by optical coherence tomographic angiography.
T he introduction of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment has lead to dramatic improvements in the visual prognosis of patients with neovascular age-related macular degeneration (nAMD). [1] [2] [3] [4] Despite the lack of consensus regarding the various therapeutic regimens used by retina specialists, the overall morphologic and functional outcomes far surpass the natural course of nAMD. 5 Monthly anti-VEGF treatment has been shown to achieve the best functional results in randomized controlled multicenter studies; however, this approach involves a significant treatment burden and an indefinite number of intravitreal injections. Furthermore, monthly treatment is cost intensive and could play a role in the development of geographic atrophy in patients with nAMD. 6 To reduce this treatment burden and associated adverse effects, pro re nata and treatand-extend regimens have been introduced, and both have been shown to achieve comparable results to monthly treatment. 5 Tailoring the treatment intervals for each patient, however, can be challenging and involves a long process of trial and error. Furthermore, many patients present with already treated choroidal neovascularization (CNV), having received previous anti-VEGF treatment elsewhere, a group of patients usually not represented in clinical trials.
Optical coherence tomographic angiography (OCTA), a functional extension of conventional OCT, provides high-resolution imaging of the microvasculature in CNV lesions. In contrast to dye-based angiography, OCTA does not show vessel leakage, thereby facilitating an unadulterated and detailed evaluation of CNV vascular morphology. Different CNV shapes and structural features and their response to anti-VEGF treatment have been demonstrated by OCTA. [7] [8] [9] [10] [11] Several OCTA studies have explored qualitative CNV structural features that may correlate with disease activity, but these have had conflicting results, which may, however, also be explained by different inclusion criteria. 12, 13 In the first study, there was a significant association between CNV activity and qualitative CNV parameters on OCTA, whereas this was not the case in the latter study.
Given the contradictory results of these qualitative OCTA studies, and acknowledging the importance of identifying OCTA features that may reflect CNV lesion activity, we designed this study to identify quantitative features of CNV microvascular structure on OCTA that could help guide clinical decision making during individualized anti-VEGF therapy.
Methods

Study Participants and Clinical Protocols
The study protocol and procedures adhered to the ethical tenets of the Declaration of Helsinki and were approved by Northwestern University's Institutional Review Board. Patients were recruited from the retina practice in the Department of Ophthalmology of the Feinberg School of Medicine at Northwestern University, Chicago, IL. Informed consent was obtained from each participant before inclusion in this observational study. Patients were eligible if they had a diagnosis of unilateral or bilateral CNV in the setting of AMD, as well as a course of anti-VEGF treatment of at least 12 months duration. Patients were receiving treatment either following a pro re nata or treat-and-extend regimen at the discretion of the treating physician. Eyes with central geographic atrophy or subretinal fibrosis, motion artifacts or poor OCTA image quality were excluded from the analysis.
Optical Coherence Tomographic Angiography Protocol
For OCTA imaging, a commercial spectral domain OCT device (RTVue-XR Avanti; Optovue, Inc, Fremont, CA) was used. The OCT device uses a probing light beam with a center wavelength of 840 nm and a full-width half-maximum of 45 nm. The axial scan rate is 70.000 A scans per second. For detection of blood flow, two consecutive B scans are acquired at the same position to differentiate between static tissue and particles with high signal intensity fluctuation (caused by blood flow in blood vessels). The OCTA device uses split-spectrum amplitude-decorrelation angiography to improve the performance of the vessel segmentation algorithm. 14 Optical coherence tomographic angiography volume scans measuring 3 mm · 3 mm (304 · 304 pixels), centered on the CNV membrane were acquired in approximately 3 seconds. In cases where the CNV membrane exceeded the field of view of 3 mm · 3 mm, a montage of multiple en face OCT angiography scans scans was generated using i2k Retina Pro (Version 3.0.0; DualAlign, LLC, Clifton Park, NY) and used for further analysis of the vasculature.
Postprocessing and Qualitative Evaluation of Images
Depending on the location of the CNV membrane, either the outer retinal or the choriocapillaris (CC) slab was used to best encompass the whole neovascular complex and the slab thickness manually adjusted using B-scan information. To remove projection artifacts originating from the superficial retinal capillary plexus onto the CC slab, a protocol was applied for all CC slabs using the FIJI software (ImageJ 2.0.0, imagej.net) before quantitative vessel analysis. 15 The CC en face angiographic slab was multiplied with the color-inverted superficial retinal capillary plexus en face image, resulting in an en face CC slab without flow signal from the superficial retinal capillary plexus ( Figure 1 ). Qualitative evaluation was performed by two graders (A.A.F. and P.K.R.) independently. If disagreement occurred, open adjudication between the two graders was performed to reach consensus. We evaluated several previously described qualitative features of CNV activity, including CNV shape, branching, the presence of anastomoses and vessel loops, morphology of vessel termini, and the presence of a hypointense halo around the lesion. 12 
Quantitative Measurements
After artifact removal, the CNV lesion was manually delineated in FIJI for quantitative evaluation. In cases with ill-defined lesion borders, the B-scan information was used in combination with the en face OCTA scans to delineate the boundaries of the CNV (see Figures 2 and 3) . For the quantitative analysis, we used a semiautomated, validated, open source software (Angiotool 0.5a, https://ccrod.cancer.gov/confluence/display/ROB2), to detect and calculate several morphologic and spatial parameters of the vascular network. 16 The software identifies the vascular configuration based on userdefined parameters such as vessel diameter and intensity. Furthermore, particles can be added or removed from the segmented vascular network based on userdefined size threshold. After optimizing the parameters that best delineate the vascular structure, the program segments, skeletonizes, and analyzes the explant area, vessel area, vessel density, total number of junctions, branching index, total vessel length, average vessel length, and lacunarity. For a detailed explanation of each of these parameters, we refer to a recent publication by Zudaire et al. 16 In brief, the explant area is equivalent to the total area of the manually segmented CNV complex. The vessel area is equivalent to the total area within the CNV complex showing flow signal on OCTA imaging. The vessel percentage area is the percentage of the total CNV lesion showing flow signal and can be derived from the lesion area and vessel area. Total vessel length is calculated as the sum of all vessels, whereby a vessel is defined as the distance between two junctions or between a junction and an endpoint. The junction density is calculated as the number of junctions normalized per unit area. Lacunarity is a measure of lesion inhomogeneity with higher values reflecting a more inhomogenous vascular structure. Two quantitative comparative analyses were performed. For both analyses, the patients were divided into two groups: "good responders" versus "poor responders," based on their individualized treatment intervals required to maintain a "dry retina." A dry retina was defined as the absence of subretinal or intraretinal fluid per spectral domain OCT.
Interval analysis 1: "good response" to treatment was defined as a treatment interval of 12 weeks or more, whereas "poor response" was defined as an interval of 4 weeks or less to maintain a dry retina.
Interval analysis 2: good response to treatment was defined as a treatment interval of more than 6 weeks, whereas poor response was defined as a treatment interval of 6 weeks or less.
Reproducibility. To test for reproducibility of the program, we compared the results of the Angiotool analysis using two approaches. The first approach used the same set of preset parameters for all study eyes. The second approach used individualized parameters set by the reader for each eye, so the vessels would be optimally segmented as suggested by the developers. 16 
Statistics
For statistical analysis, IBM SPSS statistics version 21 (IBM SPSS Statistics; IBM Corporation, Chicago, IL) was used. To test for reproducibility of the quantitative analysis, we calculated the intraclass correlation coefficient for lacunarity, which was the main outcome measure of this study. Independent samples Mann-Whitney U test was used to assess significant differences in quantitative findings between the good and poor responder groups. Descriptive statistics and chi-square test were used for qualitative findings. A P-value of ,0.05 was considered statistically significant.
Results
Twenty-five eyes of 23 consecutive patients (12 women and 11 men) with a median age of 76.5 years (range: 54-97 years) were included in the analysis.
Median duration from the initiation of therapy for nAMD to OCTA examination was 58 months (range: 12-112 months), with a median number of 34 anti-VEGF injections (range: 5-124). Sixteen eyes had been diagnosed with Type-1 CNV (vascularized pigment epithelial detachment), 4 eyes with Type-2 CNV (subretinal), 1 eye with a Type-3 (retinal angiomatous proliferation), and 4 eyes with a Type-4 (polypoidal) lesion as assessed by baseline fluorescein angiography and spectral domain OCT. Eight of the 25 study eyes had received anti-VEGF injections at outside institutions before presentation at Northwestern. The median treatment interval for all study eyes was 4 weeks (range: 2-6 weeks) in the "poor responder" and 11 weeks (range 9-184 weeks) in the "good responder" group. There was no significant difference between good and poor responders in the duration of treatment before the date of the OCTA examination (P = 0.152).
Results of the qualitative analysis are presented in Table 1 .
Fourteen eyes (7 good responders and 7 poor responders) met the criteria to be included in interval analysis 1. There was no significant difference in any of the analyzed parameters. Twenty-five eyes (13 good responders and 12 poor responders) were included in interval analysis 2. There was no significant difference in any of the analyzed parameters.
A detailed description of the quantitatively analyzed microvascular parameters is reported in Table 2 . The reproducibility for lacunarity showed excellent repeatability with intraclass correlation coefficient = 0.890. Therefore, we only report the individualized analysis approach.
Discussion
The study described herein was designed to identify imaging biomarkers for the response to anti-VEGF therapy in previously treated nAMD eyes. Optical coherence tomographic angiography provided an elegant means for imaging because of its high resolution and the lack of dye leakage obscuring the microvascular network. To reflect a real-world situation, only patients with previous anti-VEGF treatment and stable individualized therapy plan were included. In addition to a qualitative evaluation, we performed a quantitative analysis, and neither showed any significant difference between "good" and "poor" responders on OCTA.
In a mixed population of previously treated and treatment-naive eyes, Coscas et al 12 reported a significant association between CNV activity and qualitative CNV parameters on OCTA, such as a seafan or lacy wheel shape, the presence of tiny capillaries, anastomoses, and vessel loops, a peripheral arcade, and a hypointense halo around the lesion. In their study, they compared traditional multimodal imaging with OCTA and showed that Good Responders (n = 7), n (%)
Poor Responders (n = 7), n (%) P Good Responders (n = 13), n (%)
Poor Responders (n = 12), n (%) P Shape ("seafan" or "lacy wheel") detected (n) Numbers of eyes presenting the respective qualitative findings for the good and poor responder groups. Interval analysis 1: poor response = treatment every 4 weeks or more frequent, good response = treatment every 12 weeks or less frequent. Interval analysis 2: poor response = treatment every 6 weeks or more frequent, good response = treatment less frequent than every 6 weeks. Pearson chisquare test was used to assess significant differences between the two groups. Median quantitative features of the good responder and poor responder group and P-values calculated by the Mann-Whitney U test are presented. The vessel percentage area is the percentage of the total choroidal neovascular lesion showing flow signal in OCTA and can be derived from the lesion area and vessel area. Total vessel length is calculated as the sum of all vessels, whereby a vessel is defined as the distance between two junctions or between a junction and an endpoint. The junction density is calculated as the number of junctions normalized per unit area. Lacunarity is a measure of lesion inhomogeneity with higher values reflecting a more inhomogenous vascular structure.
CNV lesions that required treatment showed more of the mentioned findings than lesions not requiring treatment. Unlike our study, where individual qualitative parameters were compared between the good and poor responder group, Coscas et al implemented a system, where the presence of three qualitative features was required to classify a lesion as active on OCTA. Furthermore, we did not include treatment-naive eyes in our study, which also may explain the different outcomes. Miere et al, using OCTA, investigated active versus inactive CNV with a disease duration similar to ours (minimum duration of CNV of 12 months and an average 44-month history of CNV before inclusion), with the only exception that their study required the presence of subretinal fibrosis for inclusion. 13 Their analysis of microvascular patterns, such as pruned vascular tree, vascular loop, tangled network, dark halo, and large flow void, revealed no significant difference between the two groups. Using a quantitative approach, we have now investigated a similar patient cohort and confirmed the results of this latter study.
Unlike these previous studies, we found that many CNV lesions in our study did not fit any of the previously described shapes, such as a seafan, lacy wheel, or dead tree shape (see Figures 1 and 3) . Furthermore, qualitative assessments of the shape, presence of anastomoses and loops or peripheral arcade, were very subjective in nature, making it difficult to reach consensus between readers. Therefore, we focused our study on a quantitative, automated, and more objective approach. The Angiotool software offers semiautomated analysis of several morphologic and spatial vessel parameters, providing quantitative information about vessel density, branching pattern, and uniformity of the CNV microvasculature. A detailed description of the software and the evaluated parameters was published by Zudaire et al. 16 In brief, the junction density, calculated as the number of junctions normalized per unit area, can be interpreted as a measure of sprouting activity of the neovascular complex. Lacunarity represents a measure of vessel nonuniformity where higher values reflect inhomogeneity and lower values reflect a more homogenous vascular structure. 17 For the purpose of this study, we only assessed reproducibility of the lacunarity, which showed excellent reproducibility. Other measures need to be evaluated in future studies of CNV. Lacunarity was of particular interest, as it has been suggested as a surrogate parameter for vascular changes in allantoic membranes treated with angiostatic drugs. 16, 18 As observed previously by OCTA imaging, microvascular features of CNV membranes undergo a transformation when treated with anti-VEGF agents, resulting in the loss of smaller vessels and a "strengthening" of the larger trunk vessels. 7, 8 This qualitative observation would translate to (objectively quantifiable) higher lacunarity or "gapiness," with less homogenously filled space within the CNV lesion after anti-VEGF treatment. We would expect CNV membranes with more exudative activity (poor responders) to show lower lacunarity values than CNV membranes with less exudative activity (good responders). Furthermore, a difference in the junction density corresponding to a decrease in sprouting activity could be expected. Overall, however, our results showed consistently nonsignificant differences in all the tested parameters between the good and poor responders. These findings, while counter intuitive at first glance, fit well in the context of the "normalization hypothesis" that was established in angiogenesis research in oncology. 19 The normalization hypothesis states that newly formed blood vessels in tumors are abnormal in shape but acquire a more normal shape when treated with antiangiogenic agents. In this "normalization window," proangiogenic and antiangiogenic factors are kept in a delicate balance. The normalized blood vessels are characterized by a greater coverage with pericytes, are less leaky, less tortuous, and less dilated. 19 If antiangiogenic treatment is intensified, the new blood vessels become degenerative and inadequate for oxygen delivery. Based on our findings, we hypothesize that regardless of the interval or approach (pro re nata vs. treat-and-extend regimen), individualized treatment in nAMD results in a normalization of the CNV vasculature, which could explain the lack of significant difference between the good and poor responder groups.
Patients included in our study had been treated with a median of 34 anti-VEGF injections before study inclusion, and an individualized treatment regimen had already been established. We postulate that these patients were receiving sufficient anti-VEGF treatment to maintain a nonexudative state, without triggering vessel collapse. Once these lesions have achieved a therapeutic equilibrium between antiangiogenic and proangiogenic factors, we would expect the vessels to appear similar on OCTA in all treated eyes. This hypothesis could also explain the finding that geographic atrophy during anti-VEGF therapy is more likely to occur in eyes receiving monthly treatment than those treated pro re nata. 6 This could mean that in patients with CNV lesions particularly susceptible to anti-VEGF treatment, sustained monthly treatment could result in excessive pruning of vessels, causing hypoxia and, subsequently, retinal pigment epithelial and photoreceptor death. 19, 20 Future OCTA studies will be important to validate our findings and confirm signs of CNV quiescence. These studies may allow clinicians to use OCTA as a marker of vessel stability and optimum anti-VEGF therapeutic dosage.
The authors are aware of limitations of this study including the limited number of participants. Previous treatment of study eyes with differing types and total number of anti-VEGF injections was a potential confounding factor. Approximately one-third of the patients included in this study (8 of 25) had been treated at a different institution before first presentation, a scenario frequently encountered in clinical practice and often not accounted for in randomized clinical trials. Clinicians have to adapt to this circumstance and make decisions based on the "snapshot" obtained by clinical and OCT examination at a single patient visit. The signal roll-off in the choroid of the spectral domain-based OCTA device used in our study was limited. Swept-source-based OCTA machines operating at longer wavelengths could offer improved image quality and deeper penetration.
We believe that utilization of Angiotool to objectively and quantitatively evaluate CNV microvascular structure is an important strength of our study. The quantitative approach presented here illustrates a method to precisely assess even subtle differences, which might be challenging to incorporate in a solely qualitative analysis. Quantitative analysis of treatment-naive CNV using this approach could help to identify benchmark values for active versus normalized vasculature in the future. Defining target lacunarity or junction density could be an objective way of following and managing patients with CNV. Another strength is that this study was designed to reflect a real-life scenario, taking into account that most patients have already been started on anti-VEGF treatment.
In conclusion, we present a quantitative study of CNV microstructure based on OCTA imaging. There was no significant difference between eyes that required a short treatment interval and eyes that could be managed using longer treatment intervals. These results, reflecting a real-world scenario of study participants with a history of previous treatment, can be explained by vessel normalization, whereby individualized anti-VEGF treatment (regardless of treatment interval) achieved a "dynamic stability" between antiangiogenic and proangiogenic factors. Given our study population, our findings do not rule out the possibility that treatment-naive eyes may show significant baseline differences in microvascular patterns on OCTA that may be predictive of future treatment response. This is an important question that should be explored in future studies.
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